Filing Flows › Collegium Pharmaceutical (COLL) › Q2 2026 › vs Q1 2026
Collegium Pharmaceutical (COLL) Q2 2026 vs Q1 2026 (quarter over quarter)
Collegium Pharmaceutical's revenue rose $6.4M (+3%) from $194M in Q1 2026 to $200M in Q2 2026.
Collegium Pharmaceutical, Q2 2026: revenue $200M (+6% year over year), operating margin 1.9%, net loss $15.1M, operating cash flow $71.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 35.4% | 29.4% | +6.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $200M | $194M | $6.4M | +3% |
| Net loss | $15.1M | −$14.5M | $29.5M | — |
| Costs & expenses | $215M | $194M | $21.4M | +11% |
| Operating costs | $196M | $163M | $33.6M | +21% |
| Interest & other, net | $17.2M | $12.2M | $5.1M | +42% |
| Income tax | $1.5M | $4.2M | −$2.7M | -64% |
| Cost of revenue | $89.6M | $76.3M | $13.3M | +17% |
| Operating expenses | $107M | $86.3M | $20.2M | +23% |
| Operating cash sources | $86.4M | $42.6M | $43.8M | +103% |
| Depreciation & amortization | $64.8M | $55.9M | $8.8M | +16% |
| Share-based compensation | $14.5M | $10.9M | $3.6M | +33% |
| Working capital & other | $7.1M | −$24.2M | $31.3M | — |
| Net loss absorbed | $15.1M | −$14.5M | $29.5M | — |
| Operating cash flow | $71.3M | $57.1M | $14.2M | +25% |
| Free cash flow (OCF − capex) | $70.8M | $56.8M | $14.0M | +25% |
| Capital expenditures | $496K | $270K | $226K | +84% |
Questions
How much did Collegium Pharmaceutical's revenue grow quarter over quarter in Q2 2026?
Collegium Pharmaceutical's revenue rose $6.4M (+3%) from $194M in Q1 2026 to $200M in Q2 2026.